01:39 PM EDT, 07/17/2024 (MT Newswires) -- Alterity Therapeutics ( ATHE ) shares rose 13.6% in recent Wednesday trading after the company said preliminary data from a phase 2 trial showed that its investigative drug ATH434 improved symptoms in patients with multiple system atrophy.

Interim data showed that out of seven MSA patients who have completed six months of ATH434 treatment, three had reduced disability and two had stable or improved neurological symptoms, according to Alterity.

The drug was generally well-tolerated with no serious adverse events reported, the company said.

Although the data are preliminary, the company said it sees a "positive trend" with the outcomes.

Price: 2.25, Change: +0.27, Percent Change: +13.64